{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:15:43Z","timestamp":1785842143404,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ygyno.2020.09.022","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T18:18:53Z","timestamp":1600798733000},"page":"681-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States"],"prefix":"10.1016","volume":"159","author":[{"given":"Lindsey M.","family":"Charo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel F.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Plaxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.09.022_bb0005","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1001\/jama.284.22.2886","article-title":"Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy","volume":"284","author":"Gross","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM199207233270405","article-title":"Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE investigators","volume":"327","author":"Lamas","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0015","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0140-6736(93)91945-I","article-title":"Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction","volume":"342","author":"Ketley","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2020.09.022_bb0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ygyno.2020.02.018","article-title":"Rapid dissemination of practice-changing information: a longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial","volume":"157","author":"Charo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0030","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus Intraperitoneal chemotherapy plus Bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0040","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0055","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0060","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00686037","article-title":"Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells","volume":"34","author":"Ohno","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0070","first-page":"1136","article-title":"Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II)","volume":"40","author":"Meyn","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","article-title":"Intraperitoneal chemotherapy in the management of malignant disease","volume":"1","author":"Markman","year":"2001","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0090","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0095","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0100","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients","volume":"19","author":"Bakrin","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Di Giorgio","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0120","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.22797","article-title":"Racial disparities in blacks with gynecologic cancers","volume":"110","author":"Farley","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0130","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1067\/S0002-9378(03)00579-9","article-title":"Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades","volume":"189","author":"Barnholtz-Sloan","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0135","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00001648-200203000-00021","article-title":"Race, epithelial ovarian cancer survival, and membership in a large health maintenance organization","volume":"13","author":"McGuire","year":"2002","journal-title":"Epidemiology"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/gyno.2001.6536","article-title":"Survival among U.S. women with invasive epithelial ovarian cancer","volume":"84","author":"McGuire","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.04.037","article-title":"Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer","volume":"98","author":"Uyar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0150","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2014.55.3073","article-title":"Breast and ovarian cancer in the older woman","volume":"32","author":"Tew","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0160","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1200\/JCO.2014.56.7743","article-title":"Evaluation of 30-day hospital readmission after surgery for advanced-stage ovarian cancer in a medicare population","volume":"32","author":"Eskander","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0165","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer","volume":"28","author":"Zanon","year":"2004","journal-title":"World J. Surg."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","article-title":"Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer","volume":"94","author":"Rufi\u00e1n","year":"2006","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0180","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1245\/ASO.2003.01.018","article-title":"Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures","volume":"10","author":"Glehen","year":"2003","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","article-title":"Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study","volume":"113","author":"Fagotti","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13012-017-0555-2","article-title":"The physician\u2019s experience of changing clinical practice: a struggle to unlearn","volume":"12","author":"Gupta","year":"2017","journal-title":"Implement. Sci."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1377\/hlthaff.2014.0983","article-title":"Creating value in health by understanding and overcoming resistance to de-innovation","volume":"34","author":"Ubel","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ygyno.2020.09.022_bb0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0205","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-week paclitaxel for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.09.022_bb0210","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:15Z","timestamp":1758772575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820339159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090825820339159"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}